Epileptic Disorders

, 13:18 | Cite as

Treatment of malignant migrating partial epilepsy of infancy with rufinamide: report of five cases

  • Martina Vendrame
  • Annapurna Poduri
  • Tobias Loddenkemper
  • Gerhard Kluger
  • Giangennaro Coppola
  • Sanjeev V. Kothare
Original Article with Video Sequences


The syndrome of malignant migrating partial seizures of infancy (MMPEI) is characterized by early onset of multiple seizures types, highly pharmaco-resistant seizures, and overall poor prognosis. In this study, we investigated retrospectively the efficacy of rufinamide (RUF) in five infants with MMPEI, by examining seizure type and frequency, EEG features and antiepileptic drug use. The data demonstrate that two of the five patients showed good efficacy and tolerability for RUF with a > 50% reduction in seizure frequency. The use of RUF for the treatment of MMPEI may therefore provide some hope for such infants and should be further validated.

Key words

electroencephalogram multi-focal bromide migrating epilepsy of infancy rufinamide 


  1. Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65:1737–1743.PubMedCrossRefGoogle Scholar
  2. Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia 2010 (in press).Google Scholar
  3. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009; 50:1899–1909.PubMedCrossRefGoogle Scholar
  4. Cheng-Hakimian A, Anderson GD, Miller JW, Rufinamide: JW. Pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006; 60:1497–1501.PubMedCrossRefGoogle Scholar
  5. Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia 1995; 36:1017–1024.PubMedCrossRefGoogle Scholar
  6. Coppola G, Operto FF, Auricchio G, D’Amico A, Fortunato D, Pascotto A. Temporal lobe dual pathology in malignant migrating partial seizures in infancy. Epileptic Disord 2007; 9:145–148.PubMedGoogle Scholar
  7. Coppola G. Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology. Epilepsia 2009; 50:49–51.PubMedCrossRefGoogle Scholar
  8. Coppola G, Grosso S, Franzoni E, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: First Italian multicenter experience. Seizure 2010; 19:587–591.PubMedCrossRefGoogle Scholar
  9. Coppola G, Grosso S, Franzoni E, et al. Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. Eur J Neurol 2011; 18:246–251.PubMedCrossRefGoogle Scholar
  10. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70:1950–1958.PubMedCrossRefGoogle Scholar
  11. Hmaimess G, Kadhim H, Nassogne MC. Bonnier C, van Rijckevorsel K. Levetiracetam in a neonate with malignant migrating partial seizures. Pediatr Neurol 2006; 34:55–59.PubMedCrossRefGoogle Scholar
  12. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009; 14:491–495.PubMedCrossRefGoogle Scholar
  13. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010; 17:546–548.PubMedCrossRefGoogle Scholar
  14. Okuda K, Yasuhara A, Kamei A, Araki A, Kitamura N, Kobayashi Y. Successful control with bromide of two patients with malignant migrating partial seizures in infancy. Brain Dev 2000; 22:56–59.PubMedCrossRefGoogle Scholar
  15. Palhagen S, Canger R, Henriksen O, van Parys JA. Riviere ME, Karolchyk MA. Rufinamide: a double-blind, placebocontrolled proof of principle trial in patients with epilepsy. Epilepsy Res 2001; 43:115–124.PubMedCrossRefGoogle Scholar
  16. Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40:1618–1626.PubMedCrossRefGoogle Scholar
  17. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49:1123–1141.PubMedCrossRefGoogle Scholar
  18. Vendrame M, Loddenkemper T, Gooty V, et al. Experience with rufinamide in a pediatric population: a single center’s experience. Pediatric Neurology 2010; 43:155–158.PubMedCrossRefGoogle Scholar
  19. Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010; 10:1–6.PubMedCrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext and Springer 2011

Authors and Affiliations

  • Martina Vendrame
    • 1
    • 2
  • Annapurna Poduri
    • 1
  • Tobias Loddenkemper
    • 1
  • Gerhard Kluger
    • 3
  • Giangennaro Coppola
    • 4
  • Sanjeev V. Kothare
    • 1
    • 5
  1. 1.Epilepsy and Clinical NeurophysiologyChildren’s Hospital BostonBostonUSA
  2. 2.Epilepsy and Clinical NeurophysiologyBoston UniversityBostonUSA
  3. 3.Epilepsiezentrum für Kinder und JugendlicheKlinik für Neuropädiatrie und Neurologische RehabilitationVogtareuthGermany
  4. 4.Clinic of Child NeuropsychiatrySecond University of NaplesNaplesItaly
  5. 5.Children’s Hospital BostonBostonUSA

Personalised recommendations